Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy

July 20, 2026

Myasthenia gravis (MG) is a chronic autoimmune disease of the neuromuscular junction in which antibodies — most commonly against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) — interfere with nerve-to-muscle signal transmission, causing fluctuating muscle weakness that worsens with activity and improves with rest.


Intravenous immunoglobulin (IVIG) plays an important role in MG management, both for acute exacerbations and as a bridge or maintenance therapy in patients with ongoing, poorly controlled disease. For stable MG patients on maintenance IVIG, home infusion therapy is an appropriate and increasingly common setting for ongoing treatment. Pharmko supports MG patients and their neurologists across 22+ states.


How IVIG Works for Myasthenia Gravis


The mechanisms by which IVIG benefits MG patients involve multiple immunomodulatory pathways:


  • Fc receptor blockade, IVIG saturates Fc receptors on immune cells, blocking their ability to bind and destroy acetylcholine receptors
  • Anti-idiotypic antibody effects, pooled IgG in IVIG preparations contains antibodies that bind and neutralize pathological anti-AChR or anti-MuSK antibodies
  • Complement inhibition, IVIG reduces complement-mediated damage at the neuromuscular junction
  • B-cell and T-cell modulation, IVIG influences the immune pathways that drive ongoing autoantibody production


The clinical effect is typically a temporary reduction in autoantibody levels and improvement in neuromuscular transmission, producing measurable improvement in strength, ptosis, diplopia, dysphagia, and respiratory function.


When IVIG Is Used in Myasthenia Gravis


Myasthenic crisis and acute exacerbations


IVIG is a first-line intervention for myasthenic crisis, a life-threatening exacerbation characterized by severe weakness of the respiratory muscles requiring intubation or intensive monitoring. Along with plasma exchange (plasmapheresis), IVIG is used to rapidly reduce autoantibody levels and restore neuromuscular function. Both are considered equivalent in efficacy for crisis management; the choice between them is guided by availability, patient tolerance, and clinical circumstances.


For acute exacerbations that fall short of crisis, worsening weakness before surgery, infection-triggered deterioration, or inadequate control on maintenance immunosuppression, IVIG provides a rapid, reliable bridge while longer-acting immunosuppressants are adjusted.


Pre-surgical preparation (thymectomy)


Patients with MG undergoing thymectomy or other major surgery often receive IVIG in the weeks before the procedure to optimize neuromuscular function and reduce the risk of post-operative myasthenic crisis. This is typically administered in a clinical setting given the procedural context.


Maintenance therapy


Some MG patients, particularly those who cannot tolerate corticosteroids or steroid-sparing agents, or who have breakthrough symptoms despite optimal oral immunosuppression, require ongoing maintenance IVIG to maintain adequate functional control. For these patients, regular infusions every 4 to 6 weeks provide consistent immunomodulation. Home infusion is appropriate for stable maintenance patients once their dose and schedule are established.


IVIG Dosing for Myasthenia Gravis


For acute exacerbations and crisis management, standard IVIG dosing is 2 g/kg total over 2 to 5 days, the same induction protocol used for other neurological indications. Clinical improvement typically begins within 3 to 7 days of completing the course and peaks at 2 to 3 weeks.


For maintenance therapy, dosing is individualized based on the patient's baseline disease severity, frequency of exacerbations, and response to treatment. Common maintenance schedules include 1 g/kg every 4 to 6 weeks, or 0.4–0.5 g/kg every 3 to 4 weeks. The neurologist adjusts the schedule based on the patient's functional trajectory and symptom pattern between doses.


IVIG vs Plasma Exchange for MG


Plasma exchange (plasmapheresis or PLEX) and IVIG are both effective for acute MG management, and both are used in clinical practice. Key differences:


  • Onset: PLEX may produce more rapid improvement (within 1–3 days) compared to IVIG (3–7 days)
  • Duration: IVIG effect typically lasts 4–8 weeks; PLEX effect is similar in duration
  • Access requirement: PLEX requires central venous access and specialized equipment; IVIG requires only a peripheral or central IV line
  • Side effects: PLEX carries risks related to catheter placement and fluid shifts; IVIG carries risks of headache, thrombosis, and kidney injury in high-risk patients
  • Availability: IVIG is more widely available and can be administered in any home infusion setting; PLEX requires specialized centers


For long-term maintenance, IVIG is more practical and widely used. PLEX is more commonly reserved for acute crises, pre-surgical optimization, and situations where IVIG is contraindicated or ineffective.


Home IVIG for Myasthenia Gravis: What to Expect


MG patients who transition to home IVIG maintenance typically have a well-established dose and schedule, have tolerated their infusions without significant reactions, and have been assessed by their neurologist as clinically stable. The home infusion experience is similar to that of other IVIG indications, a Pharmko nurse visits your home, administers pre-medications if ordered, monitors vital signs throughout the infusion, and documents the session.


Our guide on IVIG therapy at home covers the full setup process for any IVIG indication. For broader context on immune-mediated neurological conditions treated with IVIG, including CIDP and primary immune deficiency, those guides provide parallel reference points that MG patients and their families often find useful.


Insurance Coverage for IVIG in Myasthenia Gravis


IVIG is covered by Medicare Part B and most commercial insurance plans for MG when documentation supports medical necessity, confirmed diagnosis with antibody testing, severity of clinical presentation, and evidence of inadequate control or intolerance to standard immunosuppressive therapy. Pharmko manages prior authorization and works with your neurologist's office to compile the required clinical documentation and submit the authorization request.


Contact Pharmko to start MG IVIG therapy: 1-877-540-2003 · info@pharmko.com


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More